LGND News and Press, Ligand Pharmaceuticals Incorporated From 12/12/23

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, revi...

COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the three poster presentations ex...

2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. Members of Ligand’s senior management team will provide an update on the company’s strategy and portfolio as well as a multi-year financial outlook and a 20...

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with Microcystic Lymphatic Malformations U.S. FDA Breakthrough Therapy Desig...

COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had five abstracts accepted as poste...

2023-11-15 13:22:59 ET Summary Ligand Pharmaceuticals Incorporated is a biopharma company focused on developing technologies for pharmaceutical companies. The company has a wide assortment of assets it draws royalty income from and an expanding pipeline. Ligand Pharmaceuticals...

2023-11-08 22:22:05 ET Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Simon Latimer - Head-Investor Relations Todd Davis - Chief Executive Officer Matthew Korenberg - President and Chief Operat...

2023-11-08 16:43:55 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals Q3 2023 Earnings Preview Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Seeking Alpha’s Quant...

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine month...